Natera

IPO

A global leader in cfDNA testing

Public · San Carlos, United States · Founded 2004 · $310.1M raised

Employees
5001–10000
Founded
2004
Business Model
B2B
Website
natera.com
Total Funding
$310.1M
Last Round
$200.0M Series EJul 2019
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Natera is a global leader in cell-free DNA (cfDNA) testing dedicated to oncology, women's health, and organ health. The company's tests — including Signatera for cancer MRD detection, Panorama for prenatal screening, and Prospera for transplant monitoring — are backed by over 400 peer-reviewed publications and processed in CLIA-certified, CAP-accredited laboratories.

Summary

Natera is a Diagnostics company based in San Carlos, United States, founded in 2004. It has raised $310.1M in total across 4 rounds, most recently a $200.0M Series E round in Jul 2019. Investors include Capital Research and Management, Claremont Creek Ventures and OrbiMed.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Series ESeries EJul 2019
$200.0M

Sign up to see all 5 events

Funding: Seed through Series E. Amounts, valuations, and investors where available.

Investors

Similar Companies

Caris Life SciencesIPO

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...

Irving, United States1001–5000Diagnostics, Genomics
Growth EquityTotal funding$1.5BApr 2025
Foundation MedicineAcquired

Provides genomic profiling tests and data services to oncologists and biopharma partners to guide...

Cambridge, United States1001–5000Diagnostics, Genomics
Corporate RoundTotal funding$1.1BJan 2015
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series CTotal funding$435.0MJun 2021
BillionToOneIPO

BillionToOne develops single-molecule diagnostic tests that improve prenatal screening and help c...

Menlo Park, United States201–500Biotech, Diagnostics
Venture RoundTotal funding$406.0MMar 2026
Personal Genome DiagnosticsAcquired

Innovative genomic technologies to solve fundamental challenges in oncology

Baltimore, United States51–200Biotech, Diagnostics
Series CTotal funding$244.5MFeb 2021
Scipher Medicine

Precision immunology company using AI and clinico-genomic data to match autoimmune patients with ...

Boston, United States51–200Artificial Intelligence, Drug Discovery
Series DTotal funding$197.8MJul 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Natera on Indexed.vc
<a href="https://indexed.vc/companies/natera"><img src="https://indexed.vc/api/badge/company/natera" alt="Natera on Indexed.vc" width="260" height="76" /></a>